Lipocine Inc. (NASDAQ: LPCN) announced on September 10, 2026, that its management team will attend the H.C. Wainwright 28th Annual Global Investment Conference. The event is scheduled to take place in New York City, NY, from September 14 to September 16, 2026.
Management will present on Wednesday, September 16, 2026, at 10:00 a.m. ET. The presentation will be available as a live webcast and will be archived for 90 days following the event on Lipocine’s website.
In addition to the presentation, Lipocine management will meet with investors one-on-one during the conference. Interested parties are directed to contact their H.C. Wainwright representative to arrange these meetings.
Lipocine is a specialty pharmaceutical company focused on developing novel oral therapeutics. The company’s pipeline includes several drug candidates, including LPCN 1154 for postpartum depression, LPCN 2201 for major depressive disorder, LPCN 2101 for epilepsy, and LPCN 2401 for obesity management. The company also markets TLANDO, an oral prodrug of testosterone approved by the FDA for hypogonadism in adult males.
